Intranasal Dexmedetomidine for Severe Dental Anxiety: a Randomized Trial

Dental Anxiety Clinical Trial

Official title:

The Anxiolytic Effect of Intranasal Dexmedetomidine for Severely Anxious Patients in Dental Treatments

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05500261
• Other study ID #: SYSKY-2022-119-03
• Status: Not yet recruiting
• Phase: N/A
• Start date: November 1, 2022
• Est. completion date: July 23, 2023

Study information

• Verified date: July 2022
• Source: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
• Contact: Zeman Qin, Master
• Phone: 15018419746
• Email: qinzm[@]mail.sysu.edu.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Patients with dental anxiety only develop anxiety and fear about dental treatments. Patients with severe dental anxiety have difficulty cooperating with dental treatments, and can only complete dental treatments through general anesthesia, or even abandon treatments. Dexmedetomidine is a potent, highly selective α2-adrenoceptor agonist, which provides good anxiolytic, sedative and analgesic effects and is commonly used in anesthesiology and intensive care medicine departments, routinely intravenously. In recent years, intranasal administration of dexmedetomidine has also been reported for pediatric dentistry and adult alveolar surgery, showing good sedative and analgesic effects. However, these studies have problems such as single surgical types, small sample size, and few indicators analyzed. Therefore, the evaluation of intranasal administration of dexmedetomidine is still not comprehensive enough. Besides, the anxiolytic effect of dexmedetomidine for dental anxiety has not been reported yet. This project plans to carry out a randomized, double-blinded, placebo-controlled, two-stage clinical trial. We will firstly explore a reasonable dose, and secondly verify it with placebo as the control. We plan to measure the object indicators, including the NTI value, plasma cortisol, interleukin-6, blood pressure and heart rate, and to assess the subjective indicators using scales and questionnaires, thus comprehensively evaluating the effectiveness, safety and feasibility of the anxiolytic effect of intranasal dexmedetomidine for severe dental anxious patients, and preliminary exploring its mechanism additionally. We intend to help severe dental anxious patients completing dental treatments.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 30
• Est. completion date: July 23, 2023
• Est. primary completion date: July 23, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Fully understand the purpose and significance of this trial, voluntarily participate in this clinical trial, and voluntarily sign an informed consent form;

2. Age 18 to 65 years old, regardless of gender;

3. Diagnosed by a dentist and needs dental treatment;

4. Can be immediately arranged for dental treatment after being evaluated by the clinician as having no contraindications;

5. Graded as severe dental anxious (obtained using the MDAS modified dental anxiety scale);

6. After controlling the symptoms of infection if with symptoms of acute/systemic infection, and can be arranged immediately after meeting the indications for dental treatments;

7. BMI is 18.5 kg/m2~25 kg/m2;

8. After resting for 30 min, the SBP < 180 mmHg, the DBP < 110 mmHg, and the 60=HR = 120 bpm;

9. For women who have not been menopausal or who have been under 1 year of menopause, a pregnancy test (blood or urine pregnancy test) should be performed during the screening period, and then the study and administration should be carried out after the pregnancy test is negative during the screening period.

Exclusion Criteria:

1. Subjects who are not considered by the researcher to be suitable for nasal drops (such as severe rhinitis, nasal malformations, etc.);

2. Subjects with a history of severe arrhythmias such as type II or above AV block or a history of cardiac insufficiency;

3. Subjects with a history of myocardial infarction or unstable angina in the 6 months before the screening period;

4. Subjects with a history of ischemic stroke or transient ischemic attack (TIA);

5. Subjects with poor blood pressure control after drug therapy (hypertension: SBP=180 mmHg, and/or DBP=110 mmHg, or hypotension: SBP <90 mmHg and/or DBP=50 mmHg);

6. Subjects with psychiatric disorders (such as schizophrenia, anxiety, depression, etc.) and cognitive dysfunction, or have a history of epilepsy, or previous abuse of psychotropic drugs and narcotic drugs;

7. Subjects with a history of difficult airway disease or possibility, such as obstructive sleep apnea syndrome;

8. Randomly, within 1 year of random, a history of drug abuse, a history of drug abuse and a history of alcohol abuse, i.e., a subject who drank more than 2 units of alcohol per day on average (1 unit = 360 ml of beer or 45 ml of liquor or 150 ml of wine with an alcohol content of 40%);

9. Subjects who received selective alpha2-adrenoceptor agonists or antagonists within 14 days of randomization;

10. Those who are allergic to dexmedetomidine hydrochloride or items used in stomatology;

11. Pregnant or nursing women;

12. Those who have a birth plan within 30 days before the screening period and half a year after the end of the trial, and are unwilling or unable to take effective contraception measures;

13. Other circumstances in which the investigator determines that the subject is not suitable to participate in this study.

Related Conditions & MeSH terms

• Anxiety Disorders
• Dental Anxiety

Intervention

Drug:
• Dexmedetomidine
intranasal administration of dexmedetomidine

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

References & Publications (8)

Cheung CW, Ng KF, Liu J, Yuen MY, Ho MH, Irwin MG. Analgesic and sedative effects of intranasal dexmedetomidine in third molar surgery under local anaesthesia. Br J Anaesth. 2011 Sep;107(3):430-7. doi: 10.1093/bja/aer164. Epub 2011 Jun 16. — View Citation

Coursin DB, Coursin DB, Maccioli GA. Dexmedetomidine. Curr Opin Crit Care. 2001 Aug;7(4):221-6. Review. — View Citation

Liu S, Wang Y, Zhu Y, Yu T, Zhao H. Safety and sedative effect of intranasal dexmedetomidine in mandibular third molar surgery: a systematic review and meta-analysis. Drug Des Devel Ther. 2019 Apr 23;13:1301-1310. doi: 10.2147/DDDT.S194894. eCollection 20 — View Citation

Nooh N, Sheta SA, Abdullah WA, Abdelhalim AA. Intranasal atomized dexmedetomidine for sedation during third molar extraction. Int J Oral Maxillofac Surg. 2013 Jul;42(7):857-62. doi: 10.1016/j.ijom.2013.02.003. Epub 2013 Mar 14. — View Citation

Ryu DS, Lee DW, Choi SC, Oh IH. Sedation Protocol Using Dexmedetomidine for Third Molar Extraction. J Oral Maxillofac Surg. 2016 May;74(5):926.e1-7. doi: 10.1016/j.joms.2015.12.021. Epub 2016 Jan 7. — View Citation

Shetty SK, Aggarwal G. Efficacy of Intranasal Dexmedetomidine for Conscious Sedation in Patients Undergoing Surgical Removal of Impacted Third Molar: A Double-Blind Split Mouth Study. J Maxillofac Oral Surg. 2016 Dec;15(4):512-516. Epub 2016 Apr 21. — View Citation

Uusalo P, Guillaume S, Siren S, Manner T, Vilo S, Scheinin M, Saari TI. Pharmacokinetics and Sedative Effects of Intranasal Dexmedetomidine in Ambulatory Pediatric Patients. Anesth Analg. 2020 Apr;130(4):949-957. doi: 10.1213/ANE.0000000000004264. — View Citation

Yoo H, Iirola T, Vilo S, Manner T, Aantaa R, Lahtinen M, Scheinin M, Olkkola KT, Jusko WJ. Mechanism-based population pharmacokinetic and pharmacodynamic modeling of intravenous and intranasal dexmedetomidine in healthy subjects. Eur J Clin Pharmacol. 2015 Oct;71(10):1197-207. doi: 10.1007/s00228-015-1913-0. Epub 2015 Aug 2. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change of MDAS score	Dental anxious score will be accessed by modified dental anxiety scale (MDAS), and the change of MDAS score will be calculated as the scores right after dental treatments minus the initial score before intervention.	Change from baseline MDAS score right after finishing dental treatments, an average of 30 minutes
Secondary	Change of plasma cortisol concentration	The change of plasma cortisol concentration will be calculated as the values right after dental treatments minus the initial values before intervention.	Change from baseline plasma cortisol concentration right after finishing dental treatments, an average of 30 minutes
Secondary	Change of NTI score	The depth of sedation will be accessed by NTI score using Narcotrend, and the change of NTI score will be calculated as the score right after dental treatments minus the initial score before intervention.	Change from baseline NTI score right after finishing dental treatments, an average of 30 minutes
Secondary	Change of OAA/S score	OAA/S score will be accessed by observer's assessment of alertness/sedation scale (OAA/S), which also represent the depth of sedation, and the change of OAA/S score will be calculated as the score right after dental treatments minus the initial score before intervention.	Change from baseline OAA/S score right after finishing dental treatments, an average of 30 minutes
Secondary	Change of blood pressure (BP)	BP will be continuously accessed using an electrocardiogram monitor throughout the whole clinical process. BP value will be converted into mean arterial pressure (MAP) for comparison using the formula: MAP = (SBP + 2 × DBP)/3. Then the change of BP was presented as ?MAP, which was calculated as the MAP at the point with the highest SBP minus the initial MAP right before the procedure.	Change from baseline BP right after finishing dental treatments, an average of 30 minutes.
Secondary	Change of heart rate (HR)	HR will be continuously accessed using an electrocardiogram monitor throughout the whole clinical process. Change of HR equaled the corresponding HR of the highest SBP subtracted by the initial HR.	Change from baseline HR right after finishing dental treatments, an average of 30 minutes.
Secondary	Pain score	Pain score will be obtained via visual analogue scale (MDAS) for the subject to fill.	Through the completion of dental treatments, an average of 30 minutes.
Secondary	Percentage of thinking feasible of intranasal dexmedetomidine by participants	The feasibility of intranasal dexmedetomidine will be assessed through semistructured questionnaires. Items includes the reasons for nonparticipation; the acceptability of the trial and intranasal dexmedetomidine to participants; and the experience of the patients, the clinician performing the procedure, and the nursing staff taking care for patients during the study. The patients and clinic staffs filled the questionnaires right after the extraction process under our instruction. The outcome of the questionnaires was analyzed through counting and reported as a percentage (%).	Through the completion of dental treatments, an average of 30 minutes.